Pentoxifylline: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Pentoxifylline. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Nausea | 28.8% |
| Dizziness | 11.9% |
| Side effect | 9.6% |
| Dyspepsia | 9.6% |
| Belching/flatus/bloating | 9% |
| Headache | 6.2% |
| Drowsiness | 5.8% |
| Vomiting | 4.5% |
| Abdominal discomfort | 4% |
| Diarrhea | 3.4% |
| Flushing | 2.3% |
| Insomnia | 2.3% |
| Blurred vision | 2.3% |
| Angina/chest pain | 2.2% |
| Arrhythmia/palpitation | 1.7% |
| Agitation/nervousness | 1.7% |
| Tremor | 0.8% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Pentoxifylline Extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline Extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease.
Source: FDA labeling via NIH DailyMed (set edd4dbbc…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.